BGF – the UK and Ireland’s most active investor – has reported strong deal flow in Scotland and Northern Ireland in the first half of 2022, with close to £25 million having been invested into growing businesses, while exit activity has delivered a 3.5x return off four exits.
BGF is a long-term patient investor, making initial investments between £1 million to £15 million for a minority equity stake. Deals completed to-date in 2022 by BGF’s Scotland and Northern Ireland team come from a range of sectors, including life sciences, technology, manufacturing and healthcare.
Since the turn of the year, the team has completed a £1.6 million investment in Inverness med-tech firm Aiber, while Glasgow-headquartered Scottish Dental Care received a multi-million-pound minority investment to implement its ambitious growth plans. In the Northeast of Scotland, BGF led an £8 million investment round into Aberdeen-based biopharmaceutical company Elasmogen, to support its development pipeline of next-generation drugs.
